Jeffery J. Auletta

Nov 5, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.

Oct 24, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.

Oct 17, 2024 | nature.com | Niveditha Ravindra |Zoë C Wong |Jeffery J. Auletta |Steven M. Devine |Mark Litzow |Partow Kebriaei | +2 more

To the Editor:High relapse rates for patients despite potentially curative allogeneic hematopoietic cell transplant (alloHCT) remain a critical issue in acute myeloid leukemia (AML). Next-generation sequencing (NGS) represents a promising modality for measurable residual disease (MRD) testing in patients with AML, but the appropriate targets for monitoring must be defined [1,2,3,4,5,6,7].

Mar 10, 2024 | cancernetwork.com | Jeffery J. Auletta

Using HLA mismatched unrelated donor transplants for patients with graft-vs-host disease (GVHD) may increase the probability of finding a donor for patients with ethnically diverse backgrounds, Jeffery Auletta, MD, said.

Mar 8, 2024 | targetedonc.com | Jeffery J. Auletta

A study presented by Jeff Auletta, MD, at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigated the impact of a specific medication, posttransplant cyclophosphamide (PTCy), on transplant outcomes for patients with blood cancers who receive unrelated donor (URD) hematopoietic cell transplants (HCT). Traditionally, perfectly matched donors (8/8 HLA match) were preferred due to lower complication rates.